Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

被引:102
|
作者
Noguchi, M [1 ]
Hiwatashi, N [1 ]
Liu, Z [1 ]
Toyota, T [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 3, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
Crohn's disease; inflammation; mucosal immunology; soluble TNF receptor; tumour necrosis factor; ulcerative colitis;
D O I
10.1136/gut.43.2.203
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Tumour necrosis factor (TNF) alpha and TNF-beta are soluble ligands binding to TNF receptors with similar activities; soluble TNF receptors neutralise TNF activity by acting as inhibitors. Little is known about the cytokine/soluble receptor role in inflammatory bowel disease (IBD). Aims-To test the hypothesis that an imbalance in secretion between TNF and TNF inhibitors plays a role in gut inflammation in patients with IBD. Methods-The secretion of TNF-alpha, TNF-beta, and soluble TNF receptors was compared in the culture supernatants of colonic biopsy specimens and isolated lamina propria mononuclear cells from patients with active colonic IBD. Results-Spontaneous secretion of TNF-alpha in involved IBD mucosa was higher than in normal control and self limited colitis mucosa. Secretion of TNF-beta was higher in patients with Crohn's disease than in those with ulcerative colitis. Soluble TNF receptor in IBD mucosa inhibited TNF activity. Type 2 soluble receptor release from IBD mucosa was increased in active inflammation; release from lamina propria cells was not increased. Mucosal TNF-alpha production correlated with severity of disease. Conclusions-Results showed enhanced secretion of TNF-alpha but failure to release enhanced amounts of soluble TNF receptor in lamina propria mononuclear cells of patients with IBD. An imbalance in secretion between TNF and TNF inhibitor may be implicated in the pathogenesis of IBD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [31] Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey
    Oussalah, A.
    Roblin, X.
    Laharie, D.
    Filippi, J.
    Flamant, M.
    Faure, P.
    Phelip, J. -M.
    Bigard, M. -A.
    Peyrin-Biroulet, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 30 (08) : 854 - 863
  • [32] Study of tumor necrosis factor receptor in the inflammatory bowel disease
    Roberta Figueiroa Souza
    Marcos Ant?nio Ferreira Caetano
    Henrique Inhauser Riceti Magalh?es
    Patricia Castelucci
    World Journal of Gastroenterology, 2023, (18) : 2733 - 2746
  • [33] Study of tumor necrosis factor receptor in the inflammatory bowel disease
    Souza, Roberta Figueiroa
    Caetano, Marcos Antonio Ferreira
    Magalhaes, Henrique Inhauser Riceti
    Castelucci, Patricia
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2733 - 2746
  • [34] Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
    Al Sulais, Eman
    AlAmeel, Turki
    BIOLOGICS-TARGETS & THERAPY, 2020, 14 : 1 - 11
  • [35] Tumor necrosis factor family members and inflammatory bowel disease
    Wang, J
    Fu, YX
    IMMUNOLOGICAL REVIEWS, 2005, 204 : 144 - 155
  • [36] Antitumor necrosis factor treatment for pediatric inflammatory bowel disease
    de Bie, Charlotte I.
    Escher, Johanna C.
    de Ridder, Lissy
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (05) : 985 - 1002
  • [37] Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia
    Connell, W.
    Andrews, J. M.
    Brown, S.
    Sparrow, M.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (02) : 139 - 149
  • [38] Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab
    Pierik, M
    Vermeire, S
    Steen, KV
    Joossens, S
    Claessens, G
    Vlietinck, R
    Rutgeerts, P
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (03) : 303 - 310
  • [39] A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease
    Thomas, Tom
    Friedrich, Matthias
    Rich-Griffin, Charlotte
    Pohin, Mathilde
    Agarwal, Devika
    Pakpoor, Julia
    Lee, Carl
    Tandon, Ruchi
    Rendek, Aniko
    Aschenbrenner, Dominik
    Jainarayanan, Ashwin
    Voda, Alexandru
    Siu, Jacqueline H. Y.
    Sanches-Peres, Raphael
    Nee, Eloise
    Sathananthan, Dharshan
    Kotliar, Dylan
    Todd, Peter
    Kiourlappou, Maria
    Gartner, Lisa
    Ilott, Nicholas
    Issa, Fadi
    Hester, Joanna
    Turner, Jason
    Nayar, Saba
    Mackerodt, Jonas
    Zhang, Fan
    Jonsson, Anna
    Brenner, Michael
    Raychaudhuri, Soumya
    Kulicke, Ruth
    Ramsdell, Danielle
    Stransky, Nicolas
    Pagliarini, Ray
    Bielecki, Piotr
    Spies, Noah
    Marsden, Brian
    Taylor, Stephen
    Wagner, Allon
    Klenerman, Paul
    Walsh, Alissa
    Coles, Mark
    Jostins-Dean, Luke
    Powrie, Fiona M.
    Filer, Andrew
    Travis, Simon
    Uhlig, Holm H.
    Dendrou, Calliope A.
    Buckley, Christopher D.
    NATURE IMMUNOLOGY, 2024, 25 (11) : 2152 - 2165
  • [40] Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
    Andersson, Per
    Karling, Pontus
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2022, 127 (01)